Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited. METHODS: In this 3-year open-label, multicenter trial, we evaluated 708 patients who had suboptimal glycated hemoglobin levels while taking metformin and sulfonylurea therapy. Patients were randomly assigned to receive biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (twice if required). Sulfonylurea therapy was replaced by a second type of insulin if hyperglycemia became unacceptable during the first year of the study or subsequently if glycated hemoglobin levels were more than 6.5%. Outcome measures were glycated hemoglobin levels, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of hypoglycemia, and weight gain. RESULTS: Median glycated hemoglobin levels were similar for patients receiving biphasic (7.1%), prandial (6.8%), and basal (6.9%) insulin-based regimens (P=0.28). However, fewer patients had a level of 6.5% or less in the biphasic group (31.9%) than in the prandial group (44.7%, P=0.006) or in the basal group (43.2%, P=0.03), with 67.7%, 73.6%, and 81.6%, respectively, taking a second type of insulin (P=0.002). [corrected] Median rates of hypoglycemia per patient per year were lowest in the basal group (1.7), higher in the biphasic group (3.0), and highest in the prandial group (5.7) (P<0.001 for the overall comparison). The mean weight gain was higher in the prandial group than in either the biphasic group or the basal group. Other adverse event rates were similar in the three groups. CONCLUSIONS: Patients who added a basal or prandial insulin-based regimen to oral therapy had better glycated hemoglobin control than patients who added a biphasic insulin-based regimen. Fewer hypoglycemic episodes and less weight gain occurred in patients adding basal insulin. (Current Controlled Trials number, ISRCTN51125379.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because many persons do not achieve adequate glycemic control with monotherapy or are at risk for early loss of efficacy with metformin or another monotherapy, combining antihyperglycemic agents is often appropriate.1060”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1060]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationOhkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 783
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citation
Research works printed but not linked: 2
- Horvath K, 2007, Cochrane Database Syst Rev, 2, CD005613
- Siebenhofer A, 2006, Cochrane Database Syst Rev, 2, CD003287
Cited by
Items 601–666 of 666
Insulinothérapie dans le diabète de type2
Molines, L., Darmon, P., Jannot-Lamotte, M.-F., Schaepelynck, P., Tréglia, C., & Raccah, D. (2013) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(13)56365-7
Ammon, H. P. T., Burchard, A., Drexel, H., Füchtenbusch, M., Hauner, H., Matthaei, S., Merkel, M., Müller‐Wieland, D., Pfohl, M., Roden, M., et al. (2014)
Gómez‐Huelgas, R., Díez‐Espino, J., Formiga, F., Tejedor, J. L., Rodríguez‐Mañas, L., González-Sarmiento, E., Torre, E. L. M., & Sangrós, J. (2013)
(2013) · The Internet Journal of Family Practice · doi:10.5580/2ccf
“9% in the biphasic/premixed, prandial, and basal group, respectively).(36) However, fewer patients achieved glycemic targets (6.”
BackgroundDas Spektrum der Möglichkeiten wächst: Insulintherapie bei Typ-2-Diabetes heute
Siegmund, T., & Schumm‐Draeger, P. (2013) · Info Diabetologie · doi:10.1007/s15034-013-0387-3
Formen der Insulintherapie bei Typ-2-Diabetes: Die Qual der Wahl für ein geeignetes Schema
Liebl, A. (2013) · CME · doi:10.1007/s11298-013-0211-3
“Zum Beispiel sind in der 4-T-Studie mit der Analogakombinationen Insulin aspart und Insulin detemir sehr gute erapieresultate beschrieben worden [18], insbesondere wenn die erapie zunächst mit Insulin detemir begonnen und dann im zweiten Schritt durch Zugabe von Insulin aspart intensiviert wurde.”
BackgroundInfluentialClinical management of hyperglycaemia in type 2 diabetes
Matthews, D. R. (2015) · Wiley eBooks · doi:10.1002/9781119121725.ch13
Gallwitz, B., Westrup, D., Tübingen, U., & Saale, K. (2014)
Insulin for Inpatients in Noncritical Care Settings
Ismail‐Beigi, F. (2010) · Endocrine Practice · doi:10.1016/s1530-891x(20)42861-7
Tratamiento de la diabetes mellitus (III). Insulinoterapia
Carreras, G., & Pérez, A. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.012
Полторак, В. В., Кравчун, Н. А., & Gorshunska, M. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.8.72.2015.72337
Bombas de insulina en diabetes tipo 2, del fundamento a la práctica
Bolivariana, C. U., Álvarez, M. F., Barrientos, A. F. P., Bolivariana, U. P., Botero, J. F., Bolivariana, U. P., Rincón, A. R., & Bolivariana, U. P. (2017) · CES Medicina · doi:10.21615/cesmedicina.31.1.7 · Cited by 1
Diabète de type2: insulinothérapie basale, enjeux actuels et besoins non satisfaits
Rodier, M., & Schuldiner, S. (2017) · doi:10.1016/b978-2-294-74646-8.00013-4
Diabète de type2: échec de l'insulinothérapie basale
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00014-6
Schwere Diabetesnotfälle schnell erkennen!
Schmidt, R., & Palitzsch, K. (2017) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-017-0398-4
Schwere Diabetesnotfälle erkennen und schnell reagieren
Schmidt, R., & Palitzsch, K. (2018) · Pflegezeitschrift · doi:10.1007/s41906-018-0494-9
Managing the Diabetic Kidney Patient
Maxson, R., & Lisenby, K. M. (2018) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2018.04.002
A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes
Goldenberg, R., Assimakopoulos, P., Gilbert, J. D., Gottesman, I. S., & Yale, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13337
Nagy, E., & Kovács, G. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.31007
Influencia de la terapia antidiabética en la respuesta al tratamiento de la disfunción eréctil
Gutiérrez, L. S. (2017) · Gredos (University of Salamanca) · doi:10.14201/gredos.137163
HIPOGLUCEMIAS EN PACIENTES CON ENFERMEDAD RENAL CRÓNICA
Medek, G. (2018) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v51i3.108 · Cited by 2
Kreß, S. (2019) · Diabetes aktuell · doi:10.1055/a-0836-1591
Von einfach bis flexibel — zur Auswahl stehen drei Strategien: Insulintherapie bei Typ-2-Diabetes
Liebl, A. (2012) · MMW - Fortschritte der Medizin
Pankiv, V. І. (2019) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2019-2-12
Zhu, D., Li, X., Ji, J., Lu, J., Jia, W., Ji, L., & Zhang, P. (2019) · International Journal of Diabetes and Endocrinology · doi:10.11648/j.ijde.20190403.11
“of antihyperglycemic therapy and use of BI as an initial treatment in patients with inadequate glucose control with oral antidiabetic drugs (OADs) [8-12].”
BackgroundMeal-time + basal insulin therapy: Is all not well?
Home, P. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107923
Mudra, A. K. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2019.11.009
Stümvoll, M., & Tönjes, A. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0684-1 · Cited by 1
Thérapeutique des désordres glycémiques
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
Grotzke, M. P., & Jones, R. E. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4975-1.00010-3
SOP Einstellung mit Insulin in der Hausarztpraxis
Uebel, T. (2020) · Allgemeinmedizin up2date · doi:10.1055/a-1190-7945
New Era of Insulin Preparation for Once Weekly Administration
Bando, H. (2020) · Institutional Repositories DataBase (IRDB)
A Case Report: An Overweight Patient with High Dose Insulin Usage
Tel, B. M. A., & Tel, M. R. (2021) · National Journal of Health Sciences · doi:10.21089/njhs.54.0180
Challenges in Insulin Therapy for Type 2 Diabetes
Hodish, I. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01164-1
The Role of Bariatric Surgery in Obese Patients with Diabetes
Gandikota, P., & Laferrère, B. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch18
100 Jahre Insulin: Das Hormon des Lebens
Stefan, N. (2021) · Deutsches Ärzteblatt · doi:10.3238/persdia.2021.05.17.01
Ampudia‐Blasco, F. J. (2012) · Avances en Diabetología · doi:10.1016/s1134-3230(12)70017-0
Ammon, H. P. T., Burchard, A., Drexel, H., Füchtenbusch, M., Häring, H., Hauner, H., Joost, H., Matthaei, S., Merkel, M., Müller‐Wieland, D., et al. (2014) · Springer eBooks · doi:10.1007/978-3-642-41358-2_4
Hypoglycemia in Diabetes Mellitus
Alsahli, M., & Gerich, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_19 · Cited by 1
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Hypoglycemia in Diabetes Mellitus
Alsahli, M., & Gerich, J. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_19-1
Type 2 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch10
Hudson, M., & Palermo, N. E. (2020) · Springer eBooks · doi:10.1007/978-3-319-47771-8_14
(2009) · British Journal of Hospital Medicine · doi:10.12968/hmed.2009.70.12.45502
Bilous, F. R., & Donnelly, R. (2010) · Wiley eBooks · doi:10.1002/9781444391374.ch13
Sreemantula, G. (2012) · doi:10.1007/978-1-908517-81-4_3
(2012) · Elsevier eBooks · doi:10.1016/b978-3-437-41797-9.16001-7
Strategies for the Management of Type 2 Diabetes
Winocour, P. H., & Zac‐Varghese, S. (2022) · doi:10.1093/med/9780198870197.003.0259
Davies, M. J., Alibegovic, A. C., Anil, G., Braae, U. C., Jensen, A. B., & Nordsborg, R. B. (2023) · Diabetic Medicine · doi:10.1111/dme.15267
Self-citationModeling and Optimization of Insulin Injection for Type-1 Diabetes Mellitus Management
Jadsadaphongphaibool, R., Bi, D., Lorenz, C. D., Deng, Y., & Schober, R. (2025) · IEEE Transactions on Molecular Biological and Multi-Scale Communications · doi:10.1109/tmbmc.2025.3559470 · Cited by 1
Danne, T., Freckmann, G., Kautzky‐Willer, A., Lang, U. E., Lehmann, R., Pfohl, M., Schloot, N. C., & Schumm‐Draeger, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-41358-2_3
Zainudin, A. M., Rasool, A. H. G., Yaccob, N. M., Muhamad, R., & Mohamed, W. M. I. W. (2024) · Figshare · doi:10.6084/m9.figshare.26750615
Zainudin, A. M., Rasool, A. H. G., Yaccob, N. M., Muhamad, R., & Mohamed, W. M. I. W. (2024) · Figshare · doi:10.6084/m9.figshare.26750612
Longato, E., Di Camillo, B., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2021) · Figshare · doi:10.6084/m9.figshare.17007077
Zainudin, A. M., Rasool, A. H. G., Yaccob, N. M., Muhamad, R., & Mohamed, W. M. I. W. (2024) · Figshare · doi:10.6084/m9.figshare.26750609
Zainudin, A. M., Rasool, A. H. G., Yaccob, N. M., Muhamad, R., & Mohamed, W. M. I. W. (2024) · Figshare · doi:10.6084/m9.figshare.26750618
Mertes, B., Zeise, N., Gödde, S., Kramer, G., Kloos, C., Klinge, A., & Uebel, T. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0009 · Cited by 1
Khatib, O. E., Chiha, M., Jarad, O., Salloum, C., Baba, K. E., Dajani, R., Shaqfa, S. A., & Hajj, S. E. (2026) · Experimental and Clinical Transplantation · doi:10.6002/ect.2025.0180 · Cited by 1
Gfi1 : a new target for diabetes therapy
Napolitano, T. (2017) · theses.fr (ABES) · doi:10.70675/aaf52a4az6ce1z446czae57z0d918d5706d5
Shabani, Z., Haxhija, E., & Drishti, E. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02378-9
Malkin, S. J. P., Kandalam, S., Guareschi, G., D’Angiolella, L. S., & Hunt, B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71144
Albasheer, O., Mohamed, A. H., Abdalghani, N., Hamdi, A. A., Ayish, D. A. M., Ayish, F., Alssum, A., Maashi, A. Y., Hassan, L. A. M. E., Madkhali, T., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1843227
The Role of Diabetes Technology in Primary Care
Martens, T. W. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.09.001
Advancing nursing jurisdiction in diabetes care
Davis, R. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 1
Insulintherapie bei Typ-2-Diabetes mellitus
Stulnig, T. M. (2014) · Der Diabetologe · doi:10.1007/s11428-013-1151-y
Metadata
- Authors
- Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K.
- Affiliations
- University of Oxford (GB)
- University of Leicester (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-29
- Volume
- 361
- Issue
- 18
- Pages
- 1736-1747
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2057595002
- Cited by
- 667
- References
- 26
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 27 · 2018: 33 · 2017: 45 · 2016: 46 · 2015: 49 · 2014: 68 · 2013: 60 · 2012: 78
- FWCI
- 57.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin therapy, biphasic insulin aspart, insulin detemir, basal insulin, HbA1c, glycemic control, hypoglycemia, weight gain, metformin, sulfonylureas
- MeSH terms
- Administration, Oral, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.